This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2008 Jul;26(6):545-52.

doi: 10.1080/07357900801971024.

HER2-positive breast cancer: current treatment strategies

Edith A Perez¹, Mansoina Baweja

Affiliations

PMID: 18584344
DOI: 10.1080/07357900801971024

Review

HER2-positive breast cancer: current treatment strategies

Edith A Perez et al. Cancer Invest. 2008 Jul.

. 2008 Jul;26(6):545-52.

doi: 10.1080/07357900801971024.

Authors

Edith A Perez¹, Mansoina Baweja

Affiliation

¹ Mayo Clinic, Jacksonville, Florida, USA.

PMID: 18584344
DOI: 10.1080/07357900801971024

No abstract available

PubMed Disclaimer

Similar articles

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N, Safra T. Yaal-Hahoshen N, et al. Isr Med Assoc J. 2006 Jun;8(6):416-21. Isr Med Assoc J. 2006. PMID: 16833172 Review. No abstract available.
HER-2/neu expression in primary and metastatic breast cancer.
Lower EE, Glass E, Blau R, Harman S. Lower EE, et al. Breast Cancer Res Treat. 2009 Jan;113(2):301-6. doi: 10.1007/s10549-008-9931-6. Epub 2008 Feb 14. Breast Cancer Res Treat. 2009. PMID: 18273700
Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
[No authors listed] [No authors listed] Prescrire Int. 2013 Feb;22(135):39. Prescrire Int. 2013. PMID: 23444499 Review.
[Systemic pharmacotherapy in breast cancer].
Boér K. Boér K. Orv Hetil. 2004 Jan 25;145(4):187-92. Orv Hetil. 2004. PMID: 14978885 Review. Hungarian. No abstract available.
Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M, Tamura K, Fujiwara Y. Shimizu C, et al. Jpn J Clin Oncol. 2009 Aug;39(8):484-90. doi: 10.1093/jjco/hyp052. Epub 2009 May 28. Jpn J Clin Oncol. 2009. PMID: 19477897

See all similar articles

Cited by

Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays.
Assadi M, Lamerz J, Jarutat T, Farfsing A, Paul H, Gierke B, Breitinger E, Templin MF, Essioux L, Arbogast S, Venturi M, Pawlak M, Langen H, Schindler T. Assadi M, et al. Mol Cell Proteomics. 2013 Sep;12(9):2615-22. doi: 10.1074/mcp.M112.023051. Epub 2013 May 7. Mol Cell Proteomics. 2013. PMID: 23653450 Free PMC article.
Inflammatory bowel disease as a model for translating the microbiome.
Huttenhower C, Kostic AD, Xavier RJ. Huttenhower C, et al. Immunity. 2014 Jun 19;40(6):843-54. doi: 10.1016/j.immuni.2014.05.013. Immunity. 2014. PMID: 24950204 Free PMC article. Review.
Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.
Cao Y, Roth M, Piperdi S, Montoya K, Sowers R, Rao P, Geller D, Houghton P, Kolb EA, Gill J, Gorlick R. Cao Y, et al. PLoS One. 2014 Aug 29;9(8):e106249. doi: 10.1371/journal.pone.0106249. eCollection 2014. PLoS One. 2014. PMID: 25170759 Free PMC article.
Renal toxicity of targeted therapies.
Kelly RJ, Billemont B, Rixe O. Kelly RJ, et al. Target Oncol. 2009 Apr;4(2):121-33. doi: 10.1007/s11523-009-0109-x. Epub 2009 May 6. Target Oncol. 2009. PMID: 19421832 Review.
Trimodal therapy in squamous cell carcinoma of the esophagus.
Matuschek C, Bölke E, Zahra T, Knoefel WT, Peiper M, Budach W, Erhardt A, Scherer A, Baldus SE, Gerber PA, Buhren BA, Schauer M, Hoff NP, Gattermann N, Orth K. Matuschek C, et al. Eur J Med Res. 2011 Oct 10;16(10):437-44. doi: 10.1186/2047-783x-16-10-437. Eur J Med Res. 2011. PMID: 22024422 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal